On June 15, the ACR and partnering physician specialist groups passed an American Medical Association (AMA) resolution opposing the proposed Medicare Part B drug payment demonstration during the AMA House of Delegates (HOD) meeting held June 11–15 in Chicago. Part B Payment Demo Resolution The resolution, which the ACR supported with the American Society of…
ACR Publishes National Research Agenda for 2016–2020
Defining new therapeutic targets and developing new therapies are among the goals of the 2016–2020 ACR National Research Agenda. So, too, is understanding early disease states, defining triggers of autoimmunity and examining disparities in access to medication and treatment.1 Charting a Course Every five years, the Committee on Research (COR) is tasked with helping chart the…
How Rheumatologists Can Engage Congress Locally, Advance Rheumatology
With limited time to spend away from your practice, you can still have an impact on issues important to Advancing Rheumatology! Below are several ways to have your voice heard, without ever leaving town. Set Up a Local Meeting with Your Elected Officials Every member of Congress has at least one local office in the…
Rheumatology Research Foundation Launches #RheumLife
May is recognized as National Arthritis Awareness Month, a time to bring attention to the more than 46 million Americans living with arthritis and related inflammatory diseases. In honor of the occasion, the Rheumatology Research Foundation is launching #RheumLife, a social media campaign to bring awareness to the severity of rheumatic disease. Through Twitter and…
Participate in Virtual Hill Meetings through the ACR
On May 12, ACR leaders representing the Board of Directors, the Affiliate Societies Council and the Committees on Government Affairs and RheumPAC took the ACR’s policy message to Capitol Hill. There is power in numbers, so we hope you will participate in your own Virtual Hill Day by visiting Legislative Action Center and letting your…
State of RheumPAC: 2015 Annual Report
Dear Friends and Colleagues, With your strong support and commitment, RheumPAC has grown again for the eighth straight year, allowing us to do even more on your behalf. Not only did we exceed our original goal by raising more than $150,000. More importantly, these donations came from nearly 350 ACR and ARHP members—a new record….
France Gets G7 to Discuss Global Regulation of Medicine Prices
PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…
Medicare Access and CHIP Reauthorization Act of 2015: What You Should Know
There is no denying that the past few years have been a time of immense change in healthcare. Sweeping pieces of legislation have fundamentally altered the way we practice medicine. This is absolutely the case when it comes to the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA, for short). MACRA is an enormous…
The ACR Joins Call for Dedicated Arthritis Research Funding to Help Veterans
Arthritis is the primary cause of disability among U.S. military veterans and the second most common reason for medical discharge from the U.S. Army. One in three veterans is diagnosed with arthritis, compared with one in five members of the general U.S. population. It is important to keep in mind that these statistics reflect only…
Opinion: Politics Should Not Trump Science in Medicine
I tell my patients there are three types of science: 1) investigative science, which sometimes gets it right; 2) science in the courtroom, which is junk science; and 3) science in Washington, D.C., which is political science. Our decisions are based on art and science; our patients’ medications are brought to market based on science….
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 86
- Next Page »